• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex.痘苗病毒 G9 蛋白 N 端附近的突变克服了 A56/K2 融合调节复合物对细胞进入和合胞体形成的限制。
J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.00077-20.
2
Experimental Evolution To Isolate Vaccinia Virus Adaptive G9 Mutants That Overcome Membrane Fusion Inhibition via the Vaccinia Virus A56/K2 Protein Complex.实验进化以分离通过痘苗病毒 A56/K2 蛋白复合物克服膜融合抑制的痘苗病毒 G9 适应性突变体。
J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.00093-20.
3
Vaccinia virus A56/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex.痘苗病毒A56/K2融合调节蛋白与进入融合复合体的A16和G9亚基相互作用。
J Virol. 2008 Jun;82(11):5153-60. doi: 10.1128/JVI.00162-08. Epub 2008 Mar 19.
4
Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH.痘苗成熟病毒融合调节蛋白 A26 与病毒进入融合复合物的 A16 和 G9 蛋白结合,并在低 pH 值下从成熟病毒粒子中解离。
J Virol. 2012 Apr;86(7):3809-18. doi: 10.1128/JVI.06081-11. Epub 2012 Jan 25.
5
Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex.痘苗病毒融合调节蛋白与多组分进入/融合复合体的关联
J Virol. 2007 Jun;81(12):6286-93. doi: 10.1128/JVI.00274-07. Epub 2007 Apr 4.
6
Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.A56和K2蛋白的表达足以抑制痘苗病毒的进入和细胞融合。
J Virol. 2009 Feb;83(4):1546-54. doi: 10.1128/JVI.01684-08. Epub 2008 Nov 26.
7
A novel mode of poxvirus superinfection exclusion that prevents fusion of the lipid bilayers of viral and cellular membranes.一种新型痘病毒超感染排除模式,可阻止病毒膜与细胞膜的脂质双层融合。
J Virol. 2014 Sep 1;88(17):9751-68. doi: 10.1128/JVI.00816-14. Epub 2014 Jun 11.
8
Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells.活感染细胞的邻近分析揭示痘病毒多成分进入融合复合物的组织。
J Virol. 2021 Jul 26;95(16):e0085221. doi: 10.1128/JVI.00852-21.
9
The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.痘苗病毒 L1 的豆蔻酸部分和氨基末端构成了进入所需的二分功能区域。
J Virol. 2012 May;86(10):5437-51. doi: 10.1128/JVI.06703-11. Epub 2012 Mar 7.
10
Loss of the vaccinia virus 35-amino acid hydrophobic O3 protein is partially compensated by mutations in the transmembrane domains of other entry proteins.痘苗病毒35个氨基酸的疏水O3蛋白的缺失可通过其他进入蛋白跨膜结构域的突变得到部分补偿。
J Virol. 2021 Mar 25;95(8). doi: 10.1128/JVI.02228-20. Epub 2021 Jan 27.

引用本文的文献

1
A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses.一种新型源自 MVA 的溶瘤痘苗病毒可诱导免疫原性肿瘤细胞死亡和强烈的抗肿瘤免疫反应。
Mol Ther. 2024 Jul 3;32(7):2406-2422. doi: 10.1016/j.ymthe.2024.05.014. Epub 2024 May 11.
2
Structural and functional analyses of viral H2 protein of the vaccinia virus entry fusion complex.痘苗病毒进入融合复合体的病毒H2蛋白的结构与功能分析
J Virol. 2023 Dec 21;97(12):e0134323. doi: 10.1128/jvi.01343-23. Epub 2023 Nov 17.

本文引用的文献

1
Nanoscale polarization of the entry fusion complex of vaccinia virus drives efficient fusion.纳米级的痘苗病毒进入融合复合物的极化驱动了有效的融合。
Nat Microbiol. 2019 Oct;4(10):1636-1644. doi: 10.1038/s41564-019-0488-4. Epub 2019 Jul 8.
2
The 2.1 Å structure of protein F9 and its comparison to L1, two components of the conserved poxvirus entry-fusion complex.蛋白 F9 的 2.1 Å 结构及其与 L1 的比较,L1 是保守痘病毒进入-融合复合物的两个组成部分之一。
Sci Rep. 2018 Nov 14;8(1):16807. doi: 10.1038/s41598-018-34244-7.
3
RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog.实验进化过程中选择的 RNA 聚合酶突变增强了一种杂种痘病毒的复制,该病毒的中间转录因子亚基被兔粘液瘤病毒的同源物取代。
J Virol. 2018 Sep 26;92(20). doi: 10.1128/JVI.01089-18. Print 2018 Oct 15.
4
Preparation of Cell Cultures and Vaccinia Virus Stocks.细胞培养物和痘苗病毒储备液的制备。
Curr Protoc Mol Biol. 2017 Jan 5;117:16.16.1-16.16.18. doi: 10.1002/cpmb.33.
5
Generation of Recombinant Vaccinia Viruses.重组痘苗病毒的产生
Curr Protoc Mol Biol. 2017 Jan 5;117:16.17.1-16.17.18. doi: 10.1002/cpmb.32.
6
Membrane fusion during poxvirus entry.痘病毒进入过程中的膜融合
Semin Cell Dev Biol. 2016 Dec;60:89-96. doi: 10.1016/j.semcdb.2016.07.015. Epub 2016 Jul 14.
7
A novel mode of poxvirus superinfection exclusion that prevents fusion of the lipid bilayers of viral and cellular membranes.一种新型痘病毒超感染排除模式,可阻止病毒膜与细胞膜的脂质双层融合。
J Virol. 2014 Sep 1;88(17):9751-68. doi: 10.1128/JVI.00816-14. Epub 2014 Jun 11.
8
Orthopoxvirus species and strain differences in cell entry.正痘病毒属种和株在细胞进入方面的差异。
Virology. 2012 Nov 25;433(2):506-12. doi: 10.1016/j.virol.2012.08.044. Epub 2012 Sep 20.
9
Poxvirus cell entry: how many proteins does it take?痘病毒细胞进入:需要多少种蛋白?
Viruses. 2012 May;4(5):688-707. doi: 10.3390/v4050688. Epub 2012 Apr 27.
10
Integrin β1 mediates vaccinia virus entry through activation of PI3K/Akt signaling.整合素β1 通过激活 PI3K/Akt 信号介导牛痘病毒进入。
J Virol. 2012 Jun;86(12):6677-87. doi: 10.1128/JVI.06860-11. Epub 2012 Apr 11.

痘苗病毒 G9 蛋白 N 端附近的突变克服了 A56/K2 融合调节复合物对细胞进入和合胞体形成的限制。

Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex.

机构信息

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

出版信息

J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.00077-20.

DOI:10.1128/JVI.00077-20
PMID:32132239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7199393/
Abstract

The entry/fusion complex (EFC) consists of 11 conserved proteins embedded in the membrane envelope of mature poxvirus particles. Poxviruses also encode proteins that localize in cell membranes and negatively regulate superinfection and syncytium formation. The vaccinia virus (VACV) A56/K2 fusion regulatory complex associates with the G9/A16 EFC subcomplex, but functional support for the importance of this interaction was lacking. Here, we describe serially passaging VACV in nonpermissive cells expressing A56/K2 as an unbiased approach to isolate and analyze escape mutants. Viruses forming large plaques in A56/K2 cells increased in successive rounds of infection, indicating the occurrence and enrichment of adaptive mutations. Sequencing of genomes of passaged and cloned viruses revealed mutations near the N terminus of the G9 open reading frame but none in A16 or other genes. The most frequent mutation was His to Tyr at amino acid 44; additional escape mutants had a His-to-Arg mutation at amino acid 44 or a duplication of amino acids 26 to 39. An adaptive Tyr-to-Cys substitution at amino acid 42 was discovered using error-prone PCR to generate additional mutations. Myristoylation of G9 was unaffected by the near-N-terminal mutations. The roles of the G9 mutations in enhancing plaque size were validated by homologous recombination. The mutants exhibited enhanced entry and spread in A56/K2 cells and induced syncytia at neutral pH in HeLa cells despite the expression of A56/K2. The data suggest that the mutations perturb the interaction of G9 with A56/K2, although some association was still detected in detergent-treated infected cell lysates. The entry of enveloped viruses is achieved by the fusion of viral and cellular membranes, a critical step in infection that determines host range and provides targets for vaccines and therapeutics. Poxviruses encode an exceptionally large number of proteins comprising the entry/fusion complex (EFC), which enables infection of diverse cells. Vaccinia virus (VACV), the prototype member of the poxvirus family, also encodes the fusion regulatory proteins A56 and K2, which are displayed on the plasma membrane and may be beneficial by preventing reinfection and cell-cell fusion. Previous studies showed that A56/K2 interacts with the G9/A16 EFC subcomplex in detergent-treated cell extracts. Functional evidence for the importance of this interaction was obtained by serially passaging wild-type VACV in cells that are nonpermissive because of A56/K2 expression. VACV mutants with amino acid substitutions or duplications near the N terminus of G9 were enriched because of their ability to overcome the block to entry imposed by A56/K2.

摘要

Entry/fusion complex (EFC) 由 11 种保守蛋白组成,嵌入成熟痘病毒粒子的膜包膜中。痘病毒还编码定位于细胞膜上的蛋白质,负调控超感染和融合体形成。牛痘病毒(VACV)A56/K2 融合调节复合物与 G9/A16 EFC 亚复合物相关联,但缺乏对这种相互作用重要性的功能支持。在这里,我们通过在表达 A56/K2 的非许可细胞中连续传代 VACV,作为分离和分析逃逸突变体的一种无偏方法。在 A56/K2 细胞中形成大斑块的病毒在连续轮次的感染中增加,表明适应性突变的发生和富集。对传代和克隆病毒基因组的测序显示,G9 开放阅读框的 N 端附近有突变,但 A16 或其他基因没有突变。最常见的突变是第 44 位氨基酸的组氨酸到酪氨酸;其他逃逸突变体的第 44 位氨基酸有组氨酸到精氨酸突变,或 26 到 39 位氨基酸的重复。使用易错 PCR 生成额外突变发现了适应性的酪氨酸到半胱氨酸取代。G9 的豆蔻酰化不受近 N 端突变的影响。同源重组验证了 G9 突变在增强斑块大小方面的作用。尽管表达了 A56/K2,但突变体在 A56/K2 细胞中表现出增强的进入和扩散,并在中性 pH 值下诱导 HeLa 细胞融合。数据表明,这些突变改变了 G9 与 A56/K2 的相互作用,尽管在去污剂处理的感染细胞裂解物中仍检测到一些关联。包膜病毒的进入是通过病毒和细胞膜的融合实现的,这是感染的一个关键步骤,决定了宿主范围,并为疫苗和治疗提供了靶点。痘病毒编码一个由融合蛋白(EFC)组成的异常大量的蛋白,使感染多样化的细胞成为可能。牛痘病毒(VACV)是痘病毒家族的原型成员,还编码融合调节蛋白 A56 和 K2,它们显示在质膜上,通过防止再感染和细胞融合可能是有益的。先前的研究表明,A56/K2 在去污剂处理的细胞提取物中与 G9/A16 EFC 亚复合物相互作用。通过在由于 A56/K2 表达而不允许的细胞中连续传代野生型 VACV,获得了该相互作用重要性的功能证据。由于其克服 A56/K2 施加的进入阻断的能力,G9 近 N 端的氨基酸取代或重复的 VACV 突变体被富集。